Lates News

On July 3, Fuhong Hanlin announced on the Hong Kong Stock Exchange that its wholly-owned subsidiary Shanghai Fuhong Hanlin Biopharmaceutical Co., Ltd. has received two GMP certificates from the Federal Agency for Medicines and Health Products in Belgium for the production of HLX11 (DS) raw material, formulation (DP) production line, and packaging production line, as well as for the production of HLX14 (DS) raw material, formulation (DP) line 2, formulation (DP) line 3, and packaging production line. This GMP certification indicates that the HLX11 and HLX14 production lines have met the EU GMP standards under the EU GMP mutual recognition system among EU Member States.